Cargando…

Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan

BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Jumpei, Hanawa, Takehisa, Matsumoto, Takahiro, Yoshikawa, Nozomi, Harada, Tsutomu, Iwahashi, Kana, Nakamura, Hidefumi, Yamatani, Akimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408926/
https://www.ncbi.nlm.nih.gov/pubmed/34465373
http://dx.doi.org/10.1186/s40780-021-00214-x
_version_ 1783746892182585344
author Saito, Jumpei
Hanawa, Takehisa
Matsumoto, Takahiro
Yoshikawa, Nozomi
Harada, Tsutomu
Iwahashi, Kana
Nakamura, Hidefumi
Yamatani, Akimasa
author_facet Saito, Jumpei
Hanawa, Takehisa
Matsumoto, Takahiro
Yoshikawa, Nozomi
Harada, Tsutomu
Iwahashi, Kana
Nakamura, Hidefumi
Yamatani, Akimasa
author_sort Saito, Jumpei
collection PubMed
description BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often compounded into a powder form by pharmacists to achieve dosage adjustments for administration to pediatric patients. However, the stability and quality of compounded clonidine powder have not been verified. The objectives of this study were to formulate a 0.2 mg/g oral clonidine hydrochloride powder and assess the stability and physical properties of this compounded product in storage. METHODS: A 0.2 mg/g clonidine powder was prepared by adding lactose monohydrate to crushed and filtrated clonidine tablets. The powder was stored in polycarbonate amber bottles or coated paper packages laminated with cellophane and polyethylene. The stability of clonidine at 25 °C ± 2 °C and 60% ± 5% relative humidity was examined over a 120-d period in “bottle (closed),” “bottle (in use),” and “laminated paper” storage conditions. Drug dissolution and powder X-ray diffraction analysis were conducted to assess physicochemical stabilities. Validated liquid chromatography-diode array detection was used to detect and quantify clonidine and its degradation product, 2,6-dichloroaniline (2,6-DCA). RESULTS: Clonidine content was maintained between 90.0 and 110.0% of the initial contents in all packaging and storage conditions. After 120 d of storage, 2,6-DCA was not detected, and no crystallographic and dissolution changes were observed. CONCLUSIONS: Compounded clonidine powder stability was maintained for 120 d at 25 °C ± 2 °C and 60% ± 5% relative humidity. This information may contribute to the management of clonidine compounded powder in community and hospital pharmacies in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-021-00214-x.
format Online
Article
Text
id pubmed-8408926
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84089262021-09-01 Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan Saito, Jumpei Hanawa, Takehisa Matsumoto, Takahiro Yoshikawa, Nozomi Harada, Tsutomu Iwahashi, Kana Nakamura, Hidefumi Yamatani, Akimasa J Pharm Health Care Sci Research Article BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often compounded into a powder form by pharmacists to achieve dosage adjustments for administration to pediatric patients. However, the stability and quality of compounded clonidine powder have not been verified. The objectives of this study were to formulate a 0.2 mg/g oral clonidine hydrochloride powder and assess the stability and physical properties of this compounded product in storage. METHODS: A 0.2 mg/g clonidine powder was prepared by adding lactose monohydrate to crushed and filtrated clonidine tablets. The powder was stored in polycarbonate amber bottles or coated paper packages laminated with cellophane and polyethylene. The stability of clonidine at 25 °C ± 2 °C and 60% ± 5% relative humidity was examined over a 120-d period in “bottle (closed),” “bottle (in use),” and “laminated paper” storage conditions. Drug dissolution and powder X-ray diffraction analysis were conducted to assess physicochemical stabilities. Validated liquid chromatography-diode array detection was used to detect and quantify clonidine and its degradation product, 2,6-dichloroaniline (2,6-DCA). RESULTS: Clonidine content was maintained between 90.0 and 110.0% of the initial contents in all packaging and storage conditions. After 120 d of storage, 2,6-DCA was not detected, and no crystallographic and dissolution changes were observed. CONCLUSIONS: Compounded clonidine powder stability was maintained for 120 d at 25 °C ± 2 °C and 60% ± 5% relative humidity. This information may contribute to the management of clonidine compounded powder in community and hospital pharmacies in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-021-00214-x. BioMed Central 2021-09-01 /pmc/articles/PMC8408926/ /pubmed/34465373 http://dx.doi.org/10.1186/s40780-021-00214-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Saito, Jumpei
Hanawa, Takehisa
Matsumoto, Takahiro
Yoshikawa, Nozomi
Harada, Tsutomu
Iwahashi, Kana
Nakamura, Hidefumi
Yamatani, Akimasa
Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title_full Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title_fullStr Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title_full_unstemmed Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title_short Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
title_sort stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408926/
https://www.ncbi.nlm.nih.gov/pubmed/34465373
http://dx.doi.org/10.1186/s40780-021-00214-x
work_keys_str_mv AT saitojumpei stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT hanawatakehisa stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT matsumototakahiro stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT yoshikawanozomi stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT haradatsutomu stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT iwahashikana stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT nakamurahidefumi stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan
AT yamataniakimasa stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan